LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

Silvio Danese  ¹     Douglas C. Wolf  ²     OLGA ALEKSEEVA  ³     Lorna Charles  ⁴     Sonia Afsari  ⁴     AnnKatrin Petersen  ⁴     James K. Sheffield  ⁴     Hongjuan Li  ⁴     Diego Silva  ⁴     Fred Lublin  ⁵     Bruce A. C. Cree  ⁶     Jeffrey Cohen  ⁷     David T. Rubin  ^8    
1 Inflammatory Bowel Diseases Center, Humanitas Clinical and Research Center IRCCS and Hunimed, Milan, Italy
² Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, United States
³ Nizhni Novgorod Regional Clinical Hospital, Nizhny, Novgorod, Russia
⁴ Bristol Myers Squibb Company, Princeton, United States
⁵ Icahn School of Medicine at Mount Sinai, New York, United States
⁶ Weill Institute for Neurosciences, University of California San Francisco, San Francisco, United States
⁷ Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, United States
⁸ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)